Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events

Summary

Behçet’s disease (BD) is a chronic inflammatory disorder in which thrombosis occurs in about 30% of patients. The prothrombotic mechanisms are unknown. Thrombophilic defects and hyperhomocysteinaemia may be involved in the pathogenesis of thrombotic events, although results have been controversial. Moreover, no information is available on this issue for eastern Spain.We studied the prevalence of inherited and acquired thrombophilic risk factors in 79 patients with BD (43 men, 36 women) who had (n = 23) or did not have (n = 56) thrombosis, and in 84 healthy control subjects (42 men, 42 women). Risk factors examined were antithrombin, protein C and protein S levels, factor V Leiden, the prothrombin G20210A mutation, the methylenetetrahydrofolate reductase C677T polymorphism, and acquired thrombophilic risk factors, including anticardiolipin antibodies, lupus anticoagulant, and serum homocysteine levels. There were no differences between patients and controls in any of the parameters studied.When we studied BD patients with and without thrombotic events, the only thrombophilic defect that differed was the prothrombin G20210A mutation: Three out of 23 patients with thrombosis were carriers, compared with none of 56 patients without thrombosis (p = 0.022).Two of the three carriers developed catastrophic or recurrent thrombotic episodes; one wasa homozygous carrier of the G20210A prothrombin mutation and the other was doubly heterozygous for the G20210A prothrombin mutation and factor V Leiden. A meta-analysis demonstrated an association of factor V Leiden and prothrombin mutation with thrombosis in BD. When studies from Turkey were excluded from the meta-analysis, only the prothrombin G20210A mutation was associated with thrombosis.

Keywords

Behçet’s disease - hyperhomocysteinaemia - thrombophilic risk factors - thrombosis - meta-analysis

• References

• 1 Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet disease. Semin Arthritis Rheum 1998; 27: 197-217.
• 2 Koc Y, Güllü I, Akpek G. et al. Vascular involvement in Behçet’s disease. J Rheumatol 1992; 19: 402-10.
• 3 Leiba M, Seligsohn U, Sidi Y. et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease. Ann Rheum Dis 2004; 63: 1445-9.
• 4 Ates A, Düzgün N, Ulu A. et al. Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet’s disease. Pathophysiol Haemost Thromb 2003; 33: 157-63.
• 5 Navarro S, Ricart JM, Medina P. et al. Activated proteinC levels in Behçet’s disease and risk of venous thrombosis. Br J Haematol 2004; 126: 550-6.
• 6 Chafa O, Fischer AM, Meriane F. et al. Behçet syndrome associated with protein S deficiency. Thromb Haemost 1992; 67: 1-3.
• 7 Mammo L, Al-Dalaan A, Bahabri SS. et al. Association of factor V Leiden with Behçet's disease. J Rheumatol 1997; 24: 2196-8.
• 8 Lee YJ, Kang SW, Yang JI. et al. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res 2002; 106: 19-24.
• 9 Gurgey A, Balta G, Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behçet’s disease. Blood Coagul Fibrinolysis 2003; 14: 121-4.
• 10 Kiraz S, Ertenli I, Öztürk MA. et al. Pathological haemostasis and prothrombotic state in Behçet’s disease. Thromb Res 2002; 105: 125-33.
• 11 Demiroglu H, Yalcin S, Buyukasik Y. et al. Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study. Ann Rheum Dis 1998; 57: 694-6.
• 12 Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behçet’s disease. J Int Med Res 1998; 26: 206-8.
• 13 Bang D, Ji HG, Choi YS. et al. Absence of lupus anticoagulants in Behçet’s disease. Yonsei Med J 1991; 32: 326-9.
• 14 Espinosa G, Font J, Tassies D. et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-43.
• 15 Gul A, Ozbek U, Ozturk C. et al. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatol 1996; 35: 1178-80.
• 16 Gul A, Aslantas AB, Tekinay T. et al. Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology (Oxford) 1999; 38: 1298-9.
• 17 Oner AF, Gurgey A, Gurler A. et al. Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol 1998; 25: 496-8.
• 18 Toydemir PB, Elhan AH, Tukun A. et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet’s disease. J Rheumatol 2000; 27: 2849-54.
• 19 Lesprit P, Wechsler B, Piette JC. et al. Activated protein C resistance caused by factor V Arg 506®Gln mutation has no role in thrombotic manifestations of Behçet's disease. Ann Rheum Dis 1995; 54: 860.
• 20 Silingardi M, Salvarani C, Boiardi L. et al. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet’s disease and deep vein thrombosis. Arthritis Rheum 2004; 51: 177-83.
• 21 Verity DH, Vaughan RW, Madanat W. et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999; 128: 352-6.
• 22 Canataroglu A, Tanriverdi K, Inal T. et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet’s disease. Rheumatol Int 2003; 23: 236-40.
• 23 Engbersen AM, Franken DG, Boers GH. et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
• 24 Altinbas A, Aytemur K, Tokgozoglu L. et al. Hyperhomocysteinaemia and activated protein C resistance in Behçet’s disease. J Intern Med 2000; 248: 267-8.
• 25 Aksu K, Turgan N, Oksel F. et al. Hyperhomocysteinaemia in Behçet’s disease. Rheumatology (Oxford) 2001; 40: 687-90.
• 26 Korkmaz C, Bozan B, Kosar M. et al. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome?. Clin Exp Rheumatol 2002; 20: S30-4.
• 27 Feki M, Houman H, Ghannouchi M. et al. Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behçet’s disease. Clin Chem Lab Med 2004; 42: 1417-23.
• 28 Durand P, Prost M, Loreau N. et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 645-72.
• 29 International Study Group for Behçet’s disease. Criteria for the diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-80.
• 30 Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-65.
• 31 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg506→Gln mutation. Blood Coagul Fibrinolysis 1995; 06: 245-8.
• 32 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 33 Skibola CF, Smith MT, Kane E. et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999; 96: 12810-15.
• 34 Sutton AJ, Abrams KR, Jones DR. et al. Methods for meta-analysis in medical research. London: John Wiley; 2000
• 35 Mader R, Ziv M, Adawi M. et al. Thrombophilic factors and their relation to thromboembolic and other clinic manifestations in Behçet’s disease. J Rheumatol 1999; 11: 2404-8.
• 36 Lenk N, Ozet G, Alli N. et al. ProteinC and protein S activities in Behçet’s disease as risk factors of thrombosis. Int J Dermatol 1998; 37: 124-5.
• 37 Hull RG, Harris EN, Gharavi AE. et al. Anticardiolipin antibodies: occurrence in Behçet’s syndrome. Ann Rheum Dis 1984; 43: 746-8.
• 38 Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet´s disease. Int J Dermatol 2003; 346-51.
• 39 Kosar A, Haznedaroglu IC, Buyukasik Y. et al. Activated proteinC resistance in Behçet’s disease. Rheumatol Int 1998; 17: 249-50.
• 40 Souto JC, Coll I, Llobet D. et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-9.
• 41 Vayá A, Mira Y, Mateo J. et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-7.
• 42 Guillen M, Portoles CorellaD. et al. Prevalence of the methylenetetrahydrofolate reductase 677C®T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol 2001; 170: 255-6.
• 43 Mason JB, Miller JW. The effects of vitamins B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992; 669: 197-203.
• 44 Hoogeveen EK, Kostense PJ, Beks PJ. et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
• 45 Glueck CJ, Shaw P, Lang JE. et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-6.